Tag:
Lipitor
Latest Headlines
Latest Headlines
ALSO NOTED: Cell Therapeutics to bypass interim analysis; Nabi reports NicVAX data; Chinese see value in scientific failure; an
> Cell Therapeutics has decided to bypass an interim analysis of its non-Hodglin's lymphoma drug candidate Pixantrone. Instead, researchers say they will conduct a full analysis after the trial
Switching to generic statins not so healthy
Speaking of Pfizer, the company announced results from a new trial that showed statin-switching isn't such a good idea. Lipitor patients who switched to simvastatin saw their risk of cardio events
Ranbaxy, Sun race to generic Razadyne
Who's first out of the gate on a generic Razadyne? Indian drug maker Ranbaxy announced today that it got the FDA's tentative nod for its version of the dementia treatment--but so did Sun
IMS lists best drug launches of all time
It's not easy being a global pharmaceuticals company. First, you have to develop drugs--and then you have to sell them, not only to your home country, but around the world. And there lies the rub,
ALSO NOTED: Pfizer's Lipitor patent request rejected; Spherix sells InfoSpherix; and much more...
> Pfizer's request for a reissued Lipitor patent was stamped "Rejected" by the U.S. Patent and Trademark Office--but the decision is only preliminary, so the drug maker can still hope for extended
ALSO NOTED: Pfizer profit plummets; Orchestra kills HIV program; and much more...
> There's big trouble at Pfizer, where profit plunged 48 percent in the second quarter as new generics ate up market share and Lipitor sales floundered.
Pfizer halts Torcetrapib development
In a huge blow to the world's largest drug maker, Pfizer announced that it will halt development of its cholesterol drug Torcetrapib, one of the biggest drugs in Pfizer's pipeline. The decision came after an independent Data Safety Monitoring Board recommended terminating the study because of an imbalance of mortality and cardiovascular events . "Based on all the evidence we have …
Press Release: Pfizer to realign U.S. sales organization
Press Release: Pfizer to realign U.S. sales organization
Pfizer told to pack up presentation on torcetrapib
Pfizer's decision to discuss new data on its experimental cholesterol drug torcetrapib ahead of the American Heart Association's gathering in Chicago has earned the pharma giant a one-way ticket out of town. The AHA told Pfizer to pack up its data on the drug and leave, saying that Pfizer had violated strict rules against giving an advance preview on data scheduled for release at the conference. "Pfizer released the information early, and we need to uphold our policies," an AHA …
Data suggests torcetrapib raises blood pressure
New trial data demonstrates that Pfizer's cholesterol drug torcetrapib in combination with Lipitor increases blood pressure, according to a report in The New York Times . News of the serious side effect forced the company's stock down by two percent. Torcetrapib is designed to increase good cholesterol and lower bad cholesterol, and Pfizer has designated it as a major drug candidate for the company. Pfizer badly needs …
